ANL (Adlai Nortye) Inventories, Raw Materials & Components: $0.00 Mil (As of Dec. 2025)


What is Adlai Nortye Inventories, Raw Materials & Components?

Adlai Nortye ANL -1.57% Inventories, Raw Materials & Components is $0.00 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Adlai Nortye's inventories, raw materials & components for the quarter that ended in Dec. 2025 was $0.00 Mil.

Adlai Nortye Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Inventories, Raw Materials & Components Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
0.00 0.00 0.00 0.00 0.00

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adlai Nortye Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $0.00 Mil mean?
Adlai Nortye (ANL) has a Inventories, Raw Materials & Components of $0.00 Mil as of Dec. 2025. Raw materials are the components a company uses for its main products. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Inventories, Raw Materials & Components too high?
Adlai Nortye's current Inventories, Raw Materials & Components is $0.00 Mil.
How does Adlai Nortye's Inventories, Raw Materials & Components compare to PHAT and AURA?
Adlai Nortye's Inventories, Raw Materials & Components of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Inventories, Raw Materials & Components is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Inventories, Raw Materials & Components of $0.00 Mil. The current Inventories, Raw Materials & Components is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Inventories, Raw Materials & Components is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.